People · Operator
Named in public records as an officer, director or promoter · active 2011–2015 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Synlogic, Inc. | — | Biotechnology | Series C | $186.5M | $3.3B | 2011 |
| AdvanDx, Inc. | — | Biotechnology | Series A | $13.7M | $90.4M | 2015 |
| Asuragen Inc | — | Biotechnology | Series A | $12.5M | $271.1M | 2011 |
Christopher D Earl at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Christopher D Earl on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Evan S. Melrose | 2 | 5 |
| Matthew M Winkler | 2 | 2 |
| Peter Barrett | 1 | 18 |
| Michael Powell | 1 | 14 |
| Corey Goodman | 1 | 13 |
| Edward Mathers | 1 | 12 |
| Ed Mathers | 1 | 11 |
| Chau Khuong | 1 | 9 |
| Daniel Geffken | 1 | 6 |
| Lewis Geffen | 1 | 6 |
| Heiner Dreismann | 1 | 6 |
| Elaine Jones | 1 | 6 |
| Paul Miller | 1 | 5 |
| Nick Leschly | 1 | 5 |
| ANKIT MAHADEVIA | 1 | 4 |
| Corey S. Goodman | 1 | 4 |
| Elaine V. Jones | 1 | 3 |
| Dennis H. Langer | 1 | 3 |
| Matthew Winkler | 1 | 3 |
| David M Rubin | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.